<DOC>
	<DOCNO>NCT00091104</DOCNO>
	<brief_summary>RATIONALE : Inserting laboratory-treated gene person 's white blood cell may make body build immune response kill tumor cell . Giving cyclophosphamide fludarabine white blood cell infusion may suppress immune system allow tumor cell kill . Vaccines may make body build immune response kill tumor cell . Aldesleukin may stimulate person 's white blood cell kill tumor cell . Combining white blood cell infusion vaccine therapy aldesleukin may cause strong immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose gene-modified white blood cell give together cyclophosphamide , fludarabine , vaccine therapy , aldesleukin see well work treat patient metastatic melanoma .</brief_summary>
	<brief_title>Cyclophosphamide Fludarabine Followed Vaccine Therapy , Gene-Modified White Blood Cell Infusions , Aldesleukin Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety peripheral blood lymphocyte ( PBLs ) retrovirally transduce anti-MART-1 T-cell receptor ( TCR ) gene follow high-dose aldesleukin ( IL-2 ) MART-1:27-35 peptide vaccine patient HLA-A*0201-positive metastatic melanoma receive myeloablative preparative regimen comprise cyclophosphamide , fludarabine phosphate , total-body irradiation . - Determine , preliminarily , whether antitumor antigen TCR-engineered tumor-infiltrating lymphocyte PBLs follow IL-2 MART-1:26-35 nonmyeloablative lymphoid-depleting preparative regimen result clinical tumor regression patient . Secondary - Determine vivo survival TCR gene-engineered cell patient . - Evaluate , preliminarily , clinical response patient . OUTLINE : Patients resectable tumor undergo tumor biopsy . Tumor-infiltrating lymphocyte ( TILs ) tumor sample culture vitro test reactivity melanoma antigen . Patients unable undergo biopsy whose TILs grow culture assign group I II . Patients whose tumor yield TILs exhibit melanoma reactivity assign group III . Patients TILs exhibit melanoma reactivity remove study . - Autologous stem cell collection : Patients undergo stem cell collection treatment protocol NCI-03-C-0277 reinfusion myeloablation cell therapy . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) twice daily begin day 0 continue 5 day . Patients undergo stem cell collection apheresis bone marrow harvest begin day 5 continue 3 day . Some patient may receive second course G-CSF undergo additional stem cell collection apheresis undergo treatment outline group II . - Group I ( peripheral blood lymphocyte [ PBLs ] myeloablative preparative regimen ) : Patients receive myeloablative preparative regimen comprise cyclophosphamide IV 1 hour day -7 -6 , fludarabine phosphate IV 15-30 minute day -7 -3 , total-body irradiation twice daily day -3 -1 . Patients also receive autologous vitro tumor-reactive , T-cell receptor ( TCR ) gene-transduced PBLs IV 20-30 minute day 1 aldesleukin IV 15 minute every 8 hour day 1-5 , G-CSF SC daily begin day 1 continue blood count recover . - Group II ( PBLs nonmyeloablative preparative regimen ) : Patients meet eligibility criterion group I receive nonmyeloablative preparative regimen comprise cyclophosphamide IV 1 hour day -7 -6 fludarabine phosphate IV 30 minute day -5 -1 . Patients receive aldesleukin , G-CSF group I . - Group III ( autologous transduce TILs ) : Patients resect tumor yield viable TILs TILs transduce anti-MART-1 TCR gene retroviral vector . Patients receive cyclophosphamide fludarabine phosphate group II . Patients receive autologous transduce TILs IV 20-30 minute day 0 . Patients also receive G-CSF high-dose aldesleukin group I . All patient receive peptide immunization MART-1:27-35 peptide vaccine emulsify incomplete Freund 's adjuvant SC day 0-4 , 11 , 18 , 25 . In group II III , treatment may repeat 6-8 week later total 2 course absence disease progression unacceptable toxicity . Treatment may consist first type cell infusion patient may crossover receive cell infusion ( PBLs v TILs ) . After completion study treatment , patient follow periodically least 5 year . PROJECTED ACCRUAL : A total 136 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic melanoma HLAA*0201positive disease Measurable disease Refractory standard therapy , include highdose aldesleukin therapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy More 3 month Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 8.0 g/dL Lymphocyte count &gt; 500/mm^3 WBC &gt; 3,000/mm^3 No coagulation disorder Hepatic ALT AST &lt; 3 time upper limit normal Bilirubin ≤ 2.0 mg/dL ( &lt; 3.0 mg/dL patient Gilbert 's disease ) Hepatitis B antigen negative Hepatitis C antibody negative ( unless antigen negative ) Renal Creatinine ≤ 1.6 mg/dL Cardiovascular No myocardial infarction No cardiac arrhythmias No cardiac ischemia LVEF ≥ 45 % stress cardiac test* ( patient ≥ 50 year age OR history EKG abnormality ) No major cardiovascular illness stress thallium comparable test NOTE : *Stress thallium , stress MUGA , dobutamine echocardiogram , stress test Pulmonary No major respiratory illness No obstructive restrictive pulmonary disease FEV_1 ≥ 60 % predict pulmonary function test* DLCO ≥ 60 % predict ( totalbody irradiation cohort ) NOTE : *For patient prolonged history cigarette smoking symptom respiratory dysfunction Immunologic HIV negative No major immune system illness No active systemic infection opportunistic infection No primary immunodeficiency ( e.g. , autoimmune colitis Crohn 's disease ) No secondary immunodeficiency ( e.g. , due chemotherapy radiotherapy ) No history severe immediate hypersensitivity reaction study drug Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 month completion study treatment Must sign durable power attorney PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Recovered prior immunotherapy Prior immunization melanoma antigens allow Progressive disease prior immunization allow Prior cellular therapy , include vector transduction without myeloablation , allow More 6 week since prior anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) monoclonal antibody ( MDX010 ) therapy No prior antiCTLA4 antibody unless post antiCTLA4 antibody treatment colonoscopy normal biopsy Chemotherapy Recovered prior chemotherapy Endocrine therapy No concurrent systemic steroid Radiotherapy Recovered prior radiotherapy No prior significant mediastinal lung radiation ( totalbody irradiation cohort ) Surgery Not specify Other More 4 week since prior systemic therapy recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>